JANSSEN RESEARCH & DEVELOPMENT, LLC

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Employees: -

Market Cap: -

Website

Clinical Trials

A Study to Evaluate the Effectiveness and Safety of Paliperidone Palmitate in Subjects With Acute Schizophrenia

Phase 4

Completed

Conditions: Schizophrenia

Interventions: Drug: Paliperidone palmitate

First Posted Date: 2012-02-07

Last Posted Date: 2024-10-28

Lead Sponsor: Janssen Research & Development, LLC

Target Recruit Count: 212

Registration Number: NCT01527305

Safety, Tolerability and Pharmacodynamic Activity of JNJ-26528398 in Healthy Male Participants

Phase 1

Completed

Conditions: Healthy Participants

Interventions: Drug: JNJ-26528398
Drug: Placebo

First Posted Date: 2012-01-27

Last Posted Date: 2013-06-24

Lead Sponsor: Janssen Research & Development, LLC

Target Recruit Count: 19

Registration Number: NCT01520142

A Study That Provides Long-term Safety Follow-up and Examines Long-term Exposure to Abiraterone Acetate

Phase 3

Completed

Conditions: Metastatic Breast Cancer
Metastatic Castration-resistant Prostate Cancer

Interventions: Drug: Abiraterone acetate
Drug: Prednisone

First Posted Date: 2012-01-25

Last Posted Date: 2022-05-10

Lead Sponsor: Janssen Research & Development, LLC

Target Recruit Count: 32

Registration Number: NCT01517802

A Pharmacokinetic Study of Abiraterone Acetate in Patients With Severe Hepatic Impairment Compared to Patients With Normal Hepatic Function

Phase 1

Completed

Conditions: Hepatic Impairment

Interventions: Drug: Cohort 1
Drug: Cohort 2

First Posted Date: 2012-01-24

Last Posted Date: 2014-06-25

Lead Sponsor: Janssen Research & Development, LLC

Target Recruit Count: 16

Registration Number: NCT01516047

A Study of Tapentadol Immediate-Release in the Treatment of Patients With Acute Pain From Bunionectomy

Phase 3

Completed

Conditions: Hallux Valgus

Interventions: Drug: Tapentadol IR 50 mg
Drug: Tapentadol IR 75 mg
Drug: Placebo

First Posted Date: 2012-01-24

Last Posted Date: 2014-04-28

Lead Sponsor: Janssen Research & Development, LLC

Target Recruit Count: 353

Registration Number: NCT01516008

Study of Paliperidone Palmitate 3 Month and 1 Month Formulations for the Treatment of Patients With Schizophrenia

Phase 3

Completed

Conditions: Schizophrenia

Interventions: Drug: PP3M 175 mg eq.
Drug: PP1M 50 mg eq.
Drug: PP3M 263 mg eq.
Drug: PP1M 75 mg eq.
Drug: PP3M 350 mg eq.
Drug: PP1M 100 mg eq.
Drug: PP3M 525 mg eq.
Drug: PP1M 150 mg eq.
Drug: Placebo (20% Intralipid)

First Posted Date: 2012-01-24

Last Posted Date: 2016-05-02

Lead Sponsor: Janssen Research & Development, LLC

Target Recruit Count: 1429

Registration Number: NCT01515423

A Study Comparing Siltuximab Plus Best Supportive Care to Placebo Plus Best Supportive Care in Anemic Patients With International Prognostic Scoring System Low- or Intermediate-1-Risk Myelodysplastic Syndrome

Phase 2

Terminated

Conditions: Myelodysplastic Syndrome

Interventions: Drug: Placebo
Drug: Siltuximab
Drug: Best supportive care (BSC)

First Posted Date: 2012-01-20

Last Posted Date: 2014-09-29

Lead Sponsor: Janssen Research & Development, LLC

Target Recruit Count: 76

Registration Number: NCT01513317

A Study of Canagliflozin and Metformin Immediate Release (50 mg/500 mg) FDC Tablets in Healthy Volunteers

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: Canagliflozin tablets
Drug: Metformin IR tablets
Drug: Canagliflozin/metformin IR FDC tablets

First Posted Date: 2012-01-11

Last Posted Date: 2013-01-31

Lead Sponsor: Janssen Research & Development, LLC

Target Recruit Count: 64

Registration Number: NCT01508195

A Study of Canagliflozin and Metformin Immediate Release (150 mg/500 mg) FDC Tablets in Healthy Volunteers

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: Canagliflozin tablets
Drug: Metformin IR tablets
Drug: Canagliflozin/metformin IR FDC tablets

First Posted Date: 2012-01-11

Last Posted Date: 2013-01-16

Lead Sponsor: Janssen Research & Development, LLC

Target Recruit Count: 64

Registration Number: NCT01508182

Pharmacokinetic Profile of OROS Hydromorphone in Healthy Taiwanese Participants With Different Genotypes for the UGT2B7 Gene

Phase 1

Completed

Conditions: Healthy Volunteers

Interventions: Drug: Hydromorphone 16 mg

First Posted Date: 2011-12-07

Last Posted Date: 2013-03-04

Lead Sponsor: Janssen Research & Development, LLC

Target Recruit Count: 29

Registration Number: NCT01487564

© Copyright 2024. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy